查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1855587

乳糜泻治疗市场：2025-2032年全球预测（依治疗类型、药物类别、给药通路、通路、剂型、最终使用者、年龄层及适应症分期划分）

Celiac Disease Drugs Market by Therapy Type, Drug Class, Route Of Administration, Distribution Channel, Dosage Form, End User, Age Group, Indication Stage - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，乳糜泻治疗市场规模将达到 35.9 亿美元，复合年增长率为 10.95%。

关键市场统计数据
基准年 2024 15.6亿美元
预计年份：2025年 17.3亿美元
预测年份 2032 35.9亿美元
复合年增长率 (%) 10.95%

为影响乳糜泻药物研发的不断变化的治疗和商业环境提供了引人入胜的背景讯息

乳糜泻的治疗模式已从以饮食管理为主转变为以分子生物学、免疫学和製剂科学的进步为驱动的蓬勃发展的治疗领域。这种转变推动了临床治疗的深入，从透过避免麸质来控制症状，转向改善潜在的疾病机制、促进黏膜癒合和减少长期併发症。这促使业界、临床实践和相关人员在评估各种机会的同时，权衡临床相关性与供应和报销的实际情况。

同时，患者的期望也在不断变化。公众意识的提高、诊断演算法的改进以及患者权益倡导的加强，都推动了对能够减轻日常生活负担并切实改善生活品质的治疗方法的需求。同时，监管机构和支付方也不断完善评估疗效和长期价值的架构。所有这些因素共同构成了一个复杂且动态的环境，在这个环境中，治疗方法创新必须在临床上可靠、商业性可行且运作上可行，才能被广泛采用。

对重塑乳糜泻治疗药物临床开发、给药模式和商业化路径的变革性转变进行策略性概述

治疗领域正经历多重整合的转变，这些转变正在重新调整研发者和医疗保健系统的优先事项。首先，作用机制多样化正在加速。旨在降解摄取麸质的酵素疗法、旨在抑制抗原特异性免疫反应的靶向免疫调节剂以及作用于肠道菌群的益生菌，各自遵循不同的生物学原理。这种多方面的方法增加了差异化产品的可能性，同时也使不同疗法之间的比较评估变得更加复杂。

其次，治疗方式和分子创新正在改变临床试验设计和监管参与方式。生物製药和工程化小分子药物在生产、稳定性和递送方面需要考虑不同的因素，这会影响研发週期和资金投入。将口服药物与生物目标佐剂结合的混合开发策略正在兴起，旨在平衡疗效和患者便利性。第三，分销和医疗服务模式正在不断演变。线上处方服务的扩展和居家照护管理途径的日益成熟正在改变治疗药物到达患者手中的方式以及依从性监测的方式，从而影响商业模式和与支付方的关係。

生物技术创新者、合约研究製造商、专业药房和临床网路之间的策略伙伴关係变得至关重要，因为它们可以加快获取专业知识的速度，降低营运风险，并实现更灵活的商业化策略，涵盖不同的给药途径和最终用户环境。

对2025年美国关税政策变化对乳糜泻药物研发、生产和供应链的累积影响进行定性分析

近期关税政策的变化加剧了全球药品供应链的复杂性，并对乳糜泻药物的研发、生产和分销产生了连锁反应。原料药和特殊辅料关税的提高推高了新型生物製药和小分子药物的上游投入成本。为此，製药公司正在重新评估其供应商组合，加快对替代供应商的资格认证，并评估将关键生产流程外包或迁回国内的可能性，以降低贸易波动带来的风险。

这些变化也会影响临床药物采购和生产规模扩大的策略决策。在多个国家进行临床试验的公司面临运输临床实验药物和样本的物流成本不断上涨的问题。此外，关税也可能影响最终的剂型和给药途径。与稳定的口服製剂相比，依赖特殊注射给药系统或低温运输运输的生技药品治疗方法会受到更大的影响。

鑑于成本压力，支付方和采购机构也在调整合约预期，这促使製造商加强其价值主张并探索风险分担机制。整体提案，关税情势促使各方采取多管齐下的应对措施，包括供应链多元化、关键流程的策略性本地化、优先发展成本效益高的剂型，以及加强与下游分销伙伴的谈判，以确保药品的可及性和可负担性。

透过考虑治疗方法、药物类别、给药途径、分销管道、剂型、最终用户、年龄和适应症阶段等因素，提供可操作的细分洞察，从而指导策略重点。

市场细分錶明，不同类型的治疗方法——酶製剂、免疫调节剂和益生菌——具有不同的临床价值提案和操作要求。酵素製剂优先考虑口服製剂的稳定性以及在饮食方案中可预测的活性；免疫调节剂需要先进的安全性监测和肠外给药的可能性；益生菌则强调菌株选择、保质期管理和监管分类等方面的细微差别。这些差异会影响研发週期、监管策略以及获得医保认可所需的证据材料。

将药物分为生物製药和小分子药物两大类，会进一步影响生产的复杂性和供应链风险。生物製药通常需要专门的生产设施、低温运输物流和更高的资本投入，而小分子药物的生产流程可能更成熟，口服给药方式也更有弹性。将给药途径分为注射剂和口服剂，会影响患者的顺从性、即时照护、医疗保险报销模式。口服製剂可由患者自行给药，门诊病人更容易取得，而注射剂可能需要诊所或家庭护理护理师的参与。

将分销管道细分为医院药房、线上药房和零售药房，可以揭示具有商业性价值的获取途径。医院药局（包括公立和私立医院）对于在急诊和专科诊所分发生技药品仍然至关重要，而线上药局（包括非处方药和处方笺服务）则能够涵盖更广泛的地域，并提供更大的便利性。零售药局（包括连锁药局和独立药局）则支持慢性病维持治疗和第一线病患互动。剂型细分，例如注射剂、口服胶囊、口服锭剂和粉末，直接影响药物的稳定性、依从性和生产过程的权衡，进而影响定价和保质期策略。

将终端使用者细分为居家照护、医院和专科诊所，有助于明确治疗路径。居家照护支持长期维持治疗，无论是由护理师协助或是病人自行用药，都能减轻医院的负担。同时，医院和专科诊所仍然是急性期治疗和复杂免疫调节方案的核心场所。区分成人和儿童年龄组需要製定相应的安全性、剂量和製剂方案，而儿童药物的研发通常需要专门的研究和製剂。最后，将适应症分为急性期治疗和维持治疗，可以建立监管部门核准和医保报销所需的证据等级，其中急性期干预措施的评估主要依据快速临床终点，而维持治疗则通常根据疗效的持久性和长期结果来评判。

关键区域洞察：比较美洲、欧洲、中东和非洲以及亚太地区的驱动因素、采用动态和政策环境

在美洲，强大的诊断基础设施、众多的胃肠病学专家以及充满活力的风险投资和生物技术生态系统，促进了差异化治疗方法的快速临床开发和早期商业化。该地区的支付方框架通常强调疗效比较和长期结果，倾向于选择具有明确疗效的治疗方法。打入市场策略通常需要直接比较证据和真实世界结果数据，以支持高定价和纳入处方笺目录。

欧洲、中东和非洲的情况与实行单一支付方或多支付方医疗体系且专科医生资源有限的地区形成鲜明对比。欧洲监管机构强调全面的安全数据，并经常将卫生技术评估纳入报销决策。某些市场的集中采购和激烈的价格谈判要求製造商建立完善的卫生经济模型，并儘早与当地卫生部门接洽，以使临床开发和报销预期保持一致。

亚太地区由于诊断技术的扩展、专科医疗能力的提升以及公共和私人对生物技术投资的增加，展现出快速推广应用的潜力。然而，各地法规环境差异巨大，通常要求製造商制定独特的研发和商业化蓝图，以适应当地的註册要求、不同的报销机制和多样化的分销系统。在任何地区，与当地临床网路合作、投资于真实世界证据的生成以及製定灵活的定价和准入方案，都将提高成功推广应用的可能性。

公司层面的策略洞察，重点在于影响产品线优先排序、生产製造和市场进入决策的竞争与合作行为。

在乳糜泻治疗领域，主要企业正采取差异化策略，将自主研发与策略伙伴关係结合。生物技术公司通常专注于早期机制检验和市场定位，并利用目标临床终点来概念验证。大型製药公司通常透过先进的生产製造、监管专业知识和成熟的商业网络来扩大规模，并在建立伙伴关係和许可协议后，加速后期研发，以实现更广泛的市场推广。

整个製药产业都在投资提升自身能力，以降低生产风险并缩短产品上市时间。这些投资包括生技药品和小分子药物的契约製造关係、口服和粉剂製剂的专业配方技术，以及用于依从性和疗效追踪的数位化健康整合。竞争格局也正在推动互补资产的整合，包括资产收购、共同开发契约和合作商业化协议。此类合作方式有助于分散风险、集中资源进行昂贵的后期临床试验，并协调用于跨国申报的临床资料包。

最后，那些能够将临床差异化与现实的商业化计划相结合，从而持续取得成功的公司，将证据生成与支付方的期望相一致，建立可扩展的生产网络，并设计以患者为中心的交付模式，使其适用于住院、专科诊所和居家医疗管道。

为产业领导者提供行动建议，以加速乳糜泻药物的研发、优化药物可及性并建立稳健的商业化模式。

首先，透过将重要结局指标纳入临床试验设计和规划，使临床开发与支付方和患者的优先事项保持一致，以便儘早获得真实世界证据。这种方法可以缩小监管核准与支付方接受度之间的差距，并强化支持有利报销的价值主张。其次，透过对关键投入品的多个供应商进行资格认证、探索区域生产方案以及在临床可行的情况下设计尽可能减少低温运输依赖的剂型，实现供应链多元化并降低风险。这些措施可以降低关税和物流的风险，并提高对需求变化的应对力。

第三，采取适应性商业化策略，确保复杂的免疫调节方案能够获得医院和专科诊所的认可，同时利用线上处方服务和零售网路进行维持治疗。将产品上市计划与患者支持项目结合，可以提高患者依从性和改善实际疗效。第四，优先发展策略伙伴关係。与委外研发机构、专科药局和临床网路合作，可以充分利用技术优势，加速产品进入市场。最后，投资以患者为中心的製剂研发和儿科适用剂量方案，将扩大目标族群，并降低不同医疗机构采用该药物的障碍。

对用于获得有关乳糜泻药物的可靠、可操作见解的调查方法进行透明概述

本研究整合了第一手资料和第二手资料，以全面了解治疗、商业和监管方面的动态。第一手资料包括与相关人员进行结构化访谈和讨论，这些利害关係人包括临床医生、支付方代表、供应链专家、业务拓展负责人和病患权益倡导团体，旨在了解他们对未满足需求、推广障碍和证据要求的真实观点。第二手资料则包括对同侪审查文献、临床试验註册库、监管指南和公开的企业资料进行系统性回顾，以揭示发展趋势和监管机构的期望。

为了确保分析结果的稳健性，本研究采用了定性综合和跨资料来源交叉检验的方法。研究运用细分框架，从治疗方法类型、药物类别、给药途径、分销管道、剂型、最终用户、年龄层和适应症阶段等维度对研究结果进行解读。区域分析考虑了监管、支付方和医疗服务体系方面的差异。调查方法强调证据三角验证、基于情境的政策影响评估，以及将技术发现转化为相关人员可执行的策略建议。

简洁的结论整合了对相关人员在不断变化的乳糜泻治疗领域中寻求发展和引领的策略意义。

儿童乳糜泻治疗领域正日益成熟，成为一个多方面的生态系统，机制创新与复杂的商业性、通路以及支付方的证据要求，才能将临床前景转化为病患可近性。供应链和政策的发展，包括关税相关的变化，进一步凸显了设计具有韧性的研发和商业化策略的必要性。

成功将青睐那些将严谨的临床差异化与灵活的营运模式相结合、儘早与支付方和临床医生沟通以协调证据生成和价值预期、并建立与自身能力互补的伙伴关係关係的机构。透过推行以患者为中心的製剂策略、实现供应链多元化以及根据当地实际情况调整商业化策略，相关人员可以提高新型乳糜泻疗法在临床应用和永续可及性方面取得成效的几率。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 增加对口服酵素疗法的投资，以期在胃肠道中降解麸质
  • 旨在恢復肠道屏障功能的个人化益生菌配方研究进展
  • 开发旨在持续诱导患者麸质耐受性的免疫调节生技药品
  • 生技企业与学术中心之间合作的加强加速了紧密连接调变器的研究
  • 数位化依从性监测平台的应用日益普及，以提高无麸质饮食的依从性
  • First-in-Class可预防自体免疫反应的转谷氨酰胺酶2抑制剂正获得监管部门的密切关注。
  • 重点研究表位特异性肽疗法，以降低麸质诱导的免疫反应的敏感性

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依治疗类型分類的乳糜泻治疗市场

  • 酵素疗法
  • 免疫调节疗法
  • 益生菌疗法

9. 依药物类别分類的乳糜泻治疗市场

  • 生物製药
  • 低分子

10. 依给药途径分類的乳糜泻治疗市场

  • 注射
  • 口服

第十一章 依通路分類的乳糜泻治疗市场

  • 医院药房
    • 私立医院
    • 公立医院
  • 网路药房
    • 场外交易服务
    • 处方笺服务
  • 零售药房
    • 连锁药局
    • 独立药房

第十二章 依剂型分類的乳糜泻治疗市场

  • 注射
  • 口服胶囊
  • 口服锭剂
  • 粉末剂型

第十三章 依最终使用者分類的乳糜泻治疗市场

  • 居家照护
    • 护士助理管理
    • 自我管理
  • 医院
    • 私立医院
    • 公立医院
  • 专科诊所
    • 消化诊所
    • 一般诊所

14. 依年龄层分類的乳糜泻治疗市场

  • 成人
  • 孩子们

第十五章：依适应症阶段分類的乳糜泻治疗市场

  • 急性治疗
  • 维持治疗

16. 各地区乳糜泻治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 按群体分類的乳糜泻治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

18. 各国乳糜泻治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章 竞争情势

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Provention Bio, Inc.
    • Alvine Therapeutics, Inc.
    • Zedira GmbH
    • Nexpep Pty Ltd
    • Royal DSM NV
    • Innovate Biopharmaceuticals, Inc.
Product Code: MRR-4659C87123C2

The Celiac Disease Drugs Market is projected to grow by USD 3.59 billion at a CAGR of 10.95% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.56 billion
Estimated Year [2025] USD 1.73 billion
Forecast Year [2032] USD 3.59 billion
CAGR (%) 10.95%

Compelling contextual introduction to the evolving therapeutic and commercial environment shaping celiac disease drug development

Celiac disease has transitioned from a predominantly dietary management paradigm to a vibrant therapeutic landscape driven by advances in molecular biology, immunology, and formulation science. This shift has elevated the clinical ambition from symptom control through gluten avoidance to modifying underlying disease mechanisms, improving mucosal healing, and reducing long-term complications. As a result, stakeholders across industry, clinical practice, and payers now evaluate opportunities through a lens that balances clinical meaningfulness with practical delivery and reimbursement realities.

Concurrently, patient expectations are evolving. Increased awareness, improved diagnostic algorithms, and organized patient advocacy have amplified demand for therapies that reduce daily burden and provide measurable improvements in quality of life. Healthcare delivery is adapting to accommodate novel modalities and administration settings, while regulators and payers refine frameworks to assess comparative benefit and long-term value. Taken together, these factors create a complex, dynamic environment where therapeutic innovation must be clinically robust, commercially viable, and operationally executable to achieve adoption.

Strategic overview of the transformative shifts reordering clinical development, delivery models, and commercialization pathways in celiac disease therapeutics

The therapeutic landscape is experiencing multiple convergent shifts that are reshaping priorities for developers and healthcare systems. First, mechanistic diversification has accelerated: enzyme therapies aimed at degrading ingested gluten, targeted immunomodulators designed to blunt antigen-specific immune responses, and microbiome-directed probiotics each pursue distinct biological rationales. This pluralistic approach increases the probability of differentiated products while complicating comparative assessments across modalities.

Second, modality and molecule innovations have altered clinical trial design and regulatory engagement. Biologic agents and engineered small molecules require distinct manufacturing, stability, and delivery considerations, which affects timelines and capital intensity. Hybrid development strategies that pair oral formulations with targeted biologic adjuncts are emerging to reconcile efficacy with patient convenience. Third, distribution and care delivery models are evolving. Expansion of online prescription services and the maturation of homecare administration pathways are changing how therapies reach patients and how adherence is monitored, thereby influencing commercial models and payer interactions.

Finally, collaborative ecosystems are maturing; strategic partnerships between biotech innovators, contract development manufacturers, specialty pharmacies, and clinical networks are becoming essential. These alliances accelerate access to specialized capabilities, mitigate operational risk, and enable more flexible commercialization strategies that align with diverse routes of administration and end-user settings.

Qualitative analysis of the cumulative impacts of United States tariff policy shifts in 2025 on celiac disease drug development, manufacturing, and supply chains

Recent tariff policy changes have introduced added complexity to global pharmaceutical supply chains, with implications that ripple through development, manufacturing, and distribution of celiac disease therapies. Increased tariffs on active pharmaceutical ingredients and specialized excipients have raised upstream input costs for both novel biologics and small molecule formulations. In response, sponsors are reassessing supplier portfolios, accelerating qualification of alternative vendors, and evaluating nearshoring or repatriation of critical manufacturing steps to reduce exposure to trade-driven volatility.

These shifts also influence strategic decisions around clinical sourcing and manufacturing scale-up. Companies conducting multinational clinical trials face higher logistics costs for investigational product movement and sample transport, which can increase protocol complexity and necessitate greater contingency planning. Moreover, tariffs can affect choices of final dosage form and route of administration; therapies that rely on specialized injectable delivery systems or cold-chain dependent biologics may be disproportionately impacted compared with stable oral formulations.

Payers and procurement entities are also adjusting contracting expectations in light of cost pressures, prompting manufacturers to strengthen value propositions and explore risk-sharing arrangements. Overall, the tariff landscape encourages a multi-pronged response that includes supply chain diversification, strategic localization of critical processes, prioritization of cost-efficient dosage forms, and intensified negotiation with downstream distribution partners to preserve access and affordability.

Actionable segmentation insights that translate therapy, drug class, route, distribution, dosage form, end-user, age, and indication stage considerations into strategic priorities

Segmentation reveals that therapy type distinctions-enzyme therapy, immunomodulator therapy, and probiotic therapy-create discrete clinical value propositions and operational requirements. Enzyme therapies prioritize robust oral formulation stability and predictable activity across dietary contexts, immunomodulators demand sophisticated safety monitoring and potentially parenteral administration pathways, while probiotics emphasize strain selection, shelf-life management, and regulatory classification nuances. These differences influence development timelines, regulatory strategy, and the evidence package required for payer acceptance.

Drug class segmentation into biological and small molecule categories further determines manufacturing complexity and supply chain risk. Biologicals typically require specialized facilities, cold-chain logistics, and higher capital intensity, whereas small molecules offer more established manufacturing routes and potentially broader oral dosing flexibility. Route of administration segmentation between injectable and oral options affects patient adherence, site-of-care considerations, and reimbursement models; oral therapies favor self-administration and broader outpatient access, while injectables may necessitate clinic- or home-based nurse involvement.

Distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies highlights commercially relevant access routes. Hospital pharmacies, encompassing private and public hospitals, remain critical for acute and specialty clinic-dispensed biologics, while online pharmacies, including OTC and prescription services, enable broader geographic reach and convenience. Retail pharmacies, both chain and independent, support chronic maintenance therapies and front-line patient engagement. Dosage form segmentation-injectable formulation, oral capsules, oral tablets, and powder form-maps directly to stability, adherence, and manufacturing trade-offs that influence pricing and shelf-life strategies.

End-user segmentation into homecare settings, hospitals, and specialty clinics clarifies care pathways. Homecare, whether nurse assisted administration or self-administration, supports long-term maintenance therapies and reduces hospital burden, whereas hospital and specialty clinic settings remain central for acute management and complex immunomodulatory regimens. Age group segmentation, distinguishing adults and pediatrics, requires tailored safety, dosing, and formulation approaches, with pediatric development often demanding dedicated trials and formulations. Finally, indication stage segmentation between acute management and maintenance therapy shapes the evidence hierarchy needed for regulatory approval and payer reimbursement, with acute interventions often evaluated on rapid clinical endpoints and maintenance therapies judged on durability and long-term outcomes.

Key regional insights that compare drivers, adoption dynamics, and policy environments across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

In the Americas, strong diagnostic infrastructure, concentrated centers of gastroenterology expertise, and an active venture and biotech ecosystem drive rapid clinical development and early commercialization of differentiated therapies. Payer frameworks in this region often emphasize comparative effectiveness and long-term outcomes, which favors therapies with clear demonstrable benefits. Market access strategies frequently require head-to-head evidence or real-world outcomes data to support premium pricing and formulary placement.

Europe, the Middle East & Africa presents a heterogeneous landscape where single-payer and multi-payer systems contrast with regions that have limited specialist access. Regulatory pathways in Europe value comprehensive safety data and often incorporate health technology assessment into reimbursement decisions. In several markets, centralized procurement and stringent price negotiation practices encourage manufacturers to develop strong health economic models and engage early with regional health authorities to align clinical development with reimbursement expectations.

Asia-Pacific exhibits rapid adoption potential driven by expanding diagnostics, growing specialty care capacity, and increasing public and private investment in biotechnology. However, regulatory environments vary widely, and manufacturers often need tailored development and commercialization roadmaps that account for local registration requirements, differential reimbursement mechanisms, and diverse distribution ecosystems. Across all regions, collaboration with local clinical networks, investment in real-world evidence generation, and adaptive pricing or access programs enhance the likelihood of successful adoption.

Strategic company-level insights highlighting the competitive and collaborative behaviors shaping pipeline prioritization, manufacturing, and market entry decisions

Leading organizations in the celiac disease therapeutic arena are pursuing differentiated strategies that combine internal development with strategic partnerships. Biotech innovators often concentrate on early-stage mechanistic validation and niche positioning, leveraging targeted clinical endpoints to demonstrate proof of concept. Larger pharmaceutical firms typically bring scale through advanced manufacturing, regulatory expertise, and established commercial networks, enabling accelerated late-stage development and broader market rollout when partnerships or licensing agreements align.

Across the sector, companies are investing in capabilities that de-risk production and improve time-to-market. This includes contract manufacturing relationships for biologics and small molecules, specialized formulation expertise for oral and powder forms, and digital health integrations for adherence and outcome tracking. Competitive dynamics are also driving consolidation of complementary assets, whether through asset acquisitions, co-development deals, or joint commercialization agreements. This collaborative approach helps distribute risk, pool resources for expensive late-stage trials, and harmonize clinical data packages for multinational submissions.

Finally, companies that succeed most consistently are those that integrate clinical differentiation with pragmatic commercialization planning-aligning evidence generation to payer expectations, building scalable manufacturing networks, and designing patient-centric delivery models that work across inpatient, specialty clinic, and homecare channels.

Actionable recommendations for industry leaders to accelerate development, optimize access, and build resilient commercialization models for celiac therapies

First, align clinical development with payer and patient priorities by embedding outcomes that matter into trial design and by planning real-world evidence generation early. This approach reduces the gap between regulatory approval and payer acceptance and enhances the value narrative that supports favorable reimbursement. Second, diversify and de-risk supply chains by qualifying multiple suppliers for critical inputs, exploring regional manufacturing options, and designing dosage forms that minimize cold-chain dependence when clinically feasible. These steps mitigate tariff and logistics vulnerabilities and improve responsiveness to demand shifts.

Third, pursue adaptive commercialization strategies that leverage online prescription services and retail networks for maintenance therapies while reserving hospital and specialty clinic pathways for complex immunomodulatory regimens. Coupling product launch plans with tailored patient support programs can enhance adherence and real-world outcomes. Fourth, prioritize strategic collaborations-partner with contract development organizations, specialty pharmacies, and clinical networks to access technical capabilities and accelerate market entry. Finally, invest in patient-centric formulation development and pediatric-friendly dosing options to broaden addressable populations and reduce barriers to adoption across care settings.

Transparent overview of the research methodology employed to generate robust, actionable insights into celiac disease therapeutics

This research synthesized primary and secondary inputs to develop a comprehensive understanding of therapeutic, commercial, and regulatory dynamics. Primary research consisted of structured interviews and discussions with stakeholders including clinicians, payer representatives, supply chain experts, business development leaders, and patient advocacy groups to capture real-world perspectives on unmet needs, adoption barriers, and evidence requirements. Secondary research included a systematic review of peer-reviewed literature, clinical trial registries, regulatory guidelines, and publicly available company disclosures to contextualize development trends and regulatory expectations.

Analytical methods integrated qualitative synthesis with cross-validation across data sources to ensure robustness. Segmentation frameworks were applied to interpret findings across therapy type, drug class, route of administration, distribution channel, dosage form, end-user, age group, and indication stage. Regional analyses considered regulatory, payer, and delivery system heterogeneity. The methodology emphasized triangulation of evidence, scenario-based assessment of policy impacts, and the translation of technical findings into actionable strategic recommendations for stakeholders.

Concise conclusion that synthesizes strategic implications for stakeholders seeking to navigate and lead in the evolving celiac disease therapeutic landscape

The celiac disease therapeutic landscape is maturing into a multifaceted ecosystem where mechanistic innovation intersects with complex commercial and operational realities. Developers must balance scientific ambition with pragmatic considerations-manufacturing requirements, route-of-administration trade-offs, distribution pathways, and payer evidence demands-to convert clinical promise into patient access. Supply chain and policy developments, including tariff-related shifts, add further imperatives to design resilient development and commercialization strategies.

Success will favor organizations that integrate rigorous clinical differentiation with flexible operational models, that engage early with payers and clinicians to align evidence generation with value expectations, and that build partnerships to complement internal capabilities. By pursuing patient-centric formulation strategies, diversifying supply chains, and tailoring commercialization to regional idiosyncrasies, stakeholders can improve the odds of achieving both clinical impact and sustainable access for new celiac disease therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased investment in oral enzyme therapies targeting gluten breakdown in the digestive tract
  • 5.2. Advancement in personalized probiotic formulations designed to restore intestinal barrier function
  • 5.3. Development of immunomodulatory biologics aiming to induce sustained gluten tolerance in patients
  • 5.4. Rising collaboration between biotech companies and academic centers accelerating tight junction modulator research
  • 5.5. Growing adoption of digital adherence monitoring platforms to improve gluten-free diet compliance
  • 5.6. Regulatory momentum for first-in-class transglutaminase 2 inhibitors to prevent autoimmune response
  • 5.7. Focus on epitope-specific peptide therapies to desensitize immune reactions triggered by gluten

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Celiac Disease Drugs Market, by Therapy Type

  • 8.1. Enzyme Therapy
  • 8.2. Immunomodulator Therapy
  • 8.3. Probiotic Therapy

9. Celiac Disease Drugs Market, by Drug Class

  • 9.1. Biological
  • 9.2. Small Molecule

10. Celiac Disease Drugs Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral

11. Celiac Disease Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
    • 11.1.1. Private Hospital
    • 11.1.2. Public Hospital
  • 11.2. Online Pharmacies
    • 11.2.1. Otc Service
    • 11.2.2. Prescription Service
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Celiac Disease Drugs Market, by Dosage Form

  • 12.1. Injectable Formulation
  • 12.2. Oral Capsules
  • 12.3. Oral Tablets
  • 12.4. Powder Form

13. Celiac Disease Drugs Market, by End User

  • 13.1. Homecare Settings
    • 13.1.1. Nurse Assisted Administration
    • 13.1.2. Self Administration
  • 13.2. Hospitals
    • 13.2.1. Private Hospitals
    • 13.2.2. Public Hospitals
  • 13.3. Specialty Clinics
    • 13.3.1. Gastroenterology Clinics
    • 13.3.2. General Clinics

14. Celiac Disease Drugs Market, by Age Group

  • 14.1. Adults
  • 14.2. Pediatrics

15. Celiac Disease Drugs Market, by Indication Stage

  • 15.1. Acute Management
  • 15.2. Maintenance Therapy

16. Celiac Disease Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Celiac Disease Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Celiac Disease Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Takeda Pharmaceutical Company Limited
    • 19.3.2. Amgen Inc.
    • 19.3.3. Provention Bio, Inc.
    • 19.3.4. Alvine Therapeutics, Inc.
    • 19.3.5. Zedira GmbH
    • 19.3.6. Nexpep Pty Ltd
    • 19.3.7. Royal DSM N.V.
    • 19.3.8. Innovate Biopharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELIAC DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY OTC SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRESCRIPTION SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY POWDER FORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMER